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Abstract
Background: Despite recent advances in outlining the mechanisms involved in pancreatic carcinogenesis, precise
molecular pathways and cellular lineage specification remains incompletely understood.
Results: We show here that Cyr61/CCN1 play a critical role in pancreatic carcinogenesis through the induction of
EMT and stemness. Cyr61 mRNA and protein were detected in the early precursor lesions and their expression
intensified with disease progression. Cyr61/CCN1 expression was also detected in different pancreatic cancer cell
lines. The aggressive cell lines, in which the expressions of mesenchymal/stem cell molecular markers are
predominant; exhibit more Cyr61/CCN1 expression. Cyr61 expression is exorbitantly higher in cancer stem/tumor
initiating Panc-1-side-population (SP) cells. Upon Cyr61/CCN1 silencing, the aggressive behaviors are reduced by
obliterating interlinking pathobiological events such as reversing the EMT, blocking the expression of stem-cell-like
traits and inhibiting migration. In contrast, addition of Cyr61 protein in culture medium augments EMT and
stemness features in relatively less aggressive BxPC3 pancreatic cancer cells. Using a xenograft model we
demonstrated that cyr61/CCN1 silencing in Panc-1-SP cells reverses the stemness features and tumor initiating
potency of these cells. Moreover, our results imply a miRNA-based mechanism for the regulation of aggressive
behaviors of pancreatic cancer cells by Cyr61/CCN1.
Conclusions: In conclusion, the discovery of the involvement of Cyr61/CCN1 in pancreatic carcinogenesis may
represent an important marker for PDAC and suggests Cyr61/CCN1 can be a potential cancer therapeutic target.
Background
Pancreatic ductal adenocarcinoma (PDAC) is the tenth
most common cancer diagnosed in the United States
and fourth most common cause of cancer death in the
United States. The five year survival rate for patients
with pancreatic adenocarcinoma is approximately 5% [1]
with a median survival rate of 6 months or less [2].
Although improvement is being made through the
development of targeted therapies [3], the prognosis and
treatment of PDAC is still unsatisfactory. This is due
both to the late presentation and the lack of an effective
treatment strategy [2]. Therefore, there is a growing
need to understand of the mechanism(s) in the progres-
sion of pancreatic adenocarcinoma which will ultimately
lead to an improvement of treatment strategies for this
devastating disease.
Cyr61 (cysteine-rich 61) is a member of the CCN
f a m i l yo fg r o w t hf a c t o r st h a ti n c l u d e sC T G F ,N O V ,
WISP-1, WISP-2 and WISP-3 [4]. It is a 42 kDa
secreted, growth factor-inducible immediate-early
response gene [5]. Like other members of CCN-family,
Cyr61 contains four different conserved molecular
domains. These include insulin-like growth factor-
binding protein (IGFBP), the von Willebrand factor type
C repeat, the thrombospondin type 1 repeat (TSP-1)
and Carboxyl termini of several extracellular proteins
(CT) [4]. Cyr61 is known to link cell surface and
extracellular matrix and plays important roles on cell
adhesion, proliferation, migration, differentiation and
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physiological processes [4]. Except for lung cancers [6],
endometrial cancers [7] and leiomyomas [8], the level of
cyr61 expression has been found to be increased in var-
ious human cancers including breast, rhabdomyosarco-
mas, melanomas, gliomas, gastric, colon, bladder
papillomas and prostate cancers [9-13]. Over production
of Cyr61 may play a critical role in the development and
progression of these cancers; possibly through integrin-
linked kinase signal-networking [13-15]. In addition,
Cyr61 has been shown to promote invasion and metas-
tasis of tumors growing in preirradiated stroma [16].
Although its role in PDAC still remains poorly under-
stood, recent evidence showed that Cyr61 expression
was increased in metastatic lesions in a clinically rele-
vant model of pancreatic adenocarcinoma and suggested
that the interaction between Cyr61 and avb3m a yp r o -
mote the formation of peritoneal metastases [17].
To establish whether Cyr61 is indeed a critical signal-
ing factor in PDAC, we have studied the expression pro-
file of Cyr61 in human pancreatic adenocarcinoma
samples and different cell lines at protein and mRNA
levels; and determined its functional role in the develop-
ment and progression of pancreatic adenocarcinoma by
silencing Cyr61 retrovirally or exposing cells to recombi-
nant Cyr61 protein. The studies clearly implicate Cyr61
as an important factor in determining PDAC aggressive-
ness as it promotes epithelial to mesenchymal transition
(EMT), tumor stemness, in vitro migration and tumori-
genicity in xenograft model, possibly through the regula-
tion of multiple miRNAs that are known to link with
the progression of cancers and survival and the mainte-
nance of cancer stem cells [18,19]. Cyr61 could there-
fore represent an ideal target in PDAC therapy.
Results
Cyr61/CCN1 is differentially expressed in pancreatic tissue
samples
To determine the status of Cyr61 mRNA in PDAC, we
evaluated high grade primary pancreatic adenocarci-
noma tissue samples (N = 16) along with adjacent nor-
mal pancreas. We found ~81% (13 out of 16) pancreatic
cancer specimens exhibited over-expression of Cyr61
mRNA as compared to adjacent normal samples where
expression was either undetected or minimal. The distri-
bution of Cyr61 mRNA was mainly in the infiltrating
ducts and acini of the tumor area (Figure 1A, upper
panel). To validate the results of in situ hybridization,
we then determined Cyr61 protein status in PDAC by
immunohistochemistry using a tissue array slide and a
Cyr61 specific antibody. Each slide contained 63 speci-
mens and these included: ductal adenocarcinoma Grade
I (N = 10), Grade II (N = 15) and Grade III (N = 23) in
addition to normal adjacent pancreas (N = 3), chronic
pancreatitis (N = 3), mucus and digestive tumor cells
(N = 2), islet cell carcinoma (N = 6), fibrous tissue and
fatty tissue (N = 1). Data on chronic pancreatitis, muci-
nous and islet cell carcinoma were excluded from this
study. We found ~85% (53 out of 63) PDAC samples
were Cyr61 positive and the level of Cyr61 protein was
markedly higher in PDAC specimens as compared to
adjacent normal tissues where its expression was mini-
mal (Figures 1Alower panel and 1B). Cyr61 is distribu-
ted in the cytoplasm of tumor cells of the infiltrating
pancreatic ducts and acinar cells. The intensity of the
staining increased markedlya st h ed i s e a s ep r o g r e s s e d
from Grade-I to Grade III. However, the expression pro-
file was not grade-dependent (Figures 1A and 1B).
Moreover, increased level of Cyr61 protein was also
detected in histologically defined precursor lesions
(PanINs; PanIN-1A-PanIN-3) (Figure 1C).
Cyr61/CCN1 expression in pancreatic adenocarcinoma cell
lines at mRNA and protein level
Our next goal was to determine the status of Cyr61
mRNA and protein in different pancreatic cancer cell
lines. These included BxPC-3, Capan-1, Aspc-1, and
Panc-1. These cells were well-characterized from less
aggressive (i.e. BXPC-3 and Capan-1) to highly aggres-
sive cell lines (i.e. Aspc-1, and Panc-1) with varied
degrees of EMT markers [20]. Quantitative real-time
PCR, Northern blotting and Western blotting analysis
revealed that Cyr61 mRNA and protein were detected
in BxPC-1, Capan-1, AsPC-1 and Panc-1 with vary-
ing degrees of expression (Figures 2Aand 2B).T h e
highest expression of RNA and protein was detected in
Panc-1 cells followed by AsPC-1, Capan-1 and BxPC-3
(Figure 2).
Suppression of Cyr61/CCN1 inhibits in vitro migration of
pancreatic cancer cells
To investigate the pathobiological role of Cyr61 in pan-
creatic cancer, first, we determined the morphology as
well as the status of epithelial and mesenchymal/stem
cell markers in BxPC-3, Capan-1, AsPC-1 and Panc-1.
Consistent with previous work [20], we found that
BxPC-3 and Capan-1 cells are morphologically epithelial
in nature (Figure 3A), but these cells differentially
express both epithelial (i.e., Keratin-19, E-cadherin and
b-catenin) and mesenchymal (i.e., Vimentin) markers
(Figure 3B). In contrast, AsPC-1 and Panc-1 cells are
mixed populations of epithelial and spindle-shaped
mesenchymal type cells along with stemness and express
epithelial, mesenchymal and stem cell markers with
some exclusion in Panc-1 cells. These cells express only
Keratin-19 and high levels of Vimentin, Notch-1 and
Oct-4 (Figure 3B).E - c a d h e r i na n db-catenin expression
was undetected or minimally detected in Panc-1 cells
Haque et al. Molecular Cancer 2011, 10:8
http://www.molecular-cancer.com/content/10/1/8
Page 2 of 17and AsPC-1 cells. Taken together, these and previous
studies suggest that these pancreatic cancer cell lines
are a phenotypically mixed population but not identical
because they express epithelial and mesenchymal mar-
kers with varying degrees and their aggressive/metastatic
behaviors are different. Therefore, these cells can be
categorized from less aggressive (i.e., BxPC-3 and
Capan-1 cell lines) to highly aggressive (i.e., AsPC-1 and
Panc-1) with varied degrees of epithelial-mesenchymal
transition (EMT) and stemness (Figure 3C).N e x t ,w e
attempted to determine the role of Cyr61 in the mor-
phological and behavioral alterations of pancreatic can-
cer cells by focusing on in vitro migration. To do so, we
blocked the Cyr61 expression in Panc-1 cells by stable
transfection of a pSilencer 5.1-U6-retroviral vector-
containing Cyr61-specific shRNA, and we evaluated the
expression of Cyr61 in these cells. We found that more
than 95% of Cyr61’s expression was suppressed by stable
Figure 1 Differential expression of Cyr61 mRNA and protein in Normal pancreas and pancreatic ductal adenocarcinoma tissue
samples. A. The photomicrographs (upper panel and lower panel) represents the distribution pattern of Cyr61 mRNA (blue color) by in situ
hybridization using digoxigenin (DIG)-labeled PCR generated Cyr61 specific non-radioactive probe and Cyr61 protein (brown color) by
immunohistochemistry in a tissue array containing adjacent normal pancreas, and different grades of ductal adenocarcinoma (Gr-I, Gr-II and Gr-
III) respectively. Scale bars: 100μm. B. Distribution profile and labeling intensity of Cyr61 protein in PDAC tissue samples. Gr-I, Grade 1, Gr-II, Grade
II and Gr-III, Grade III. (-), No stain, (+), light brown, (++), moderately dark brown, and (+++), dark brown. C. H & E staining and
immunohistochemical identification of Cyr61 in precursor lesions of pancreatic cancers. Scale bars: 50μm.
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undetected in mismatched-shRNA transfected cells
(Figure 4A). After confirmation, the morphology of
Cyr61 positive (Panc-1
Cyr61+) and Cyr61 knockout
(Panc-1
KOCyr61) cells was evaluated. We found that the
morphology of the Panc-1 cells was markedly altered
with a transition from the mesenchymal/fibroblast-type
to the epithelial-type (Figure 4B). Finally, we deter-
mined whether Cyr61 has any role in in vitro migration
of these cells. To do so, we seeded Panc-1
Cyr61+ and
Panc-1
KOCyr61 cells in the upper chamber of the Boyden
chamber to test in vitro migration toward the serum for
24 h. We stained the migrated cells with Crystal violet,
and then performed a colorimetric (quantitative) analy-
sis using an ELISA plate reader. This study reveals that
the migration of Panc-1
KOCyr61 cells toward the serum
was significantly less as compared to Panc-1
Cyr61+ cells
(Figure 4C). The results were consistent when the para-
crine action of Cyr61 was blocked by adding a human
polyclonal anti-rabbit Cyr61 blocking antibody in the
media (Figure 4D). We repeated the experiments in
AsPC-1 cells and also found that the silencing of Cyr61
alters the morphology of AsPC-1 cells as well as signifi-
cantly blocks the in vitro migration of these cells (data
not shown). Finally, we evaluated the impact of Cyr61
on pancreatic cancer cell proliferation. We found that
blocking Cyr61 in Panc-1 cells by shRNA or a Cyr61-
specific antibody has no effect on the proliferation of
Panc-1 cells (data not shown).
Reverse EMT (epithelial-mesenchymal transition) by
blocking Cyr61/CCN1 expression
An EMT event is involved in the formation of motile
cells from parent epithelial cells that are not themselves
motile [21]. EMT is not only crucial for embryogenesis,
but this event is a prerequisite for the progression of
carcinogenesis as well. Because we found that Cyr61 is
essential for the morphological alteration (i.e. EMT) and
in vitro migration of PDAC cells, we sought to deter-
mine if Cyr61 modulates the expression of EMT and
stem cell molecular markers. To do so, expression pro-
files of different epithelial and mesenchymal markers
were evaluated in Panc-1
Cyr61+ and Panc-1
KOCyr61 cells.
In the absence of Cyr61, the epithelial markers (i.e.,
E-cadherin, b-catenin) expressions significantly increased,
while the expressions of mesenchymal/stem cell
markers (i.e., Vimentin, Notch-1, Oct-4, ABCG2 and
CD44) markedly decreased (Figures 5Aand 5B).W e
found consistent results when Cyr61 paracrine action
was blocked by the addition of Cyr61 antibody (differ-
ent concentrations) in the media of Panc-1 cell cultures
(Figure 5B). We found consistent results in AsPC-1
cell line (data not included). In order to confirm this
phenomenon, Cyr61 negative or minimal expressing
BxPC3 cells were exposed to Cyr61 recombinant pro-
tein (100 ng/ml) [22] for 48 h and morphology as well
as molecular markers of EMT and stemness were char-
acterized. We found that addition of Cyr61 in the cul-
ture media markedly enhanced the EMT and stemness
in these cells (Figure 6).
Figure 2 Expression of Cyr61 in different pancreatic cancer cell
lines. A. The bar graph indicates the quantitative relative expression
of Cyr61 in different pancreatic cancer cell lines by real time PCR. B.
Upper panel: Northern blot analysis of Cyr61 in different pancreatic
cancer cell lines using a nonradioactive digoxigenin-labeled, PCR-
generated Cyr61 specific probe. GAPDH was used as a control
probe to eliminate the loading differences. Lower panel: Immuno-
western blotting of Cyr61 in different pancreatic cancer cell lines.
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initiating cells/cancer stem cells of pancreatic cancer cells
Recently, different laboratories have characterized side
population (SP) of pancreatic cancer cells [23,24]. The
SP cells are either isolated from cell lines or xenograft
tumor cells. The SP is enriched with cancer stem
cells, forms tumors in xenograft models and exhibits
chemoresistance. Our goal was to examine the status
of Cyr61 in the SP of a pancreatic cancer cell line,
Panc-1. To do so, first, SP cells were isolated from
Panc-1
Cyr61+ and Panc-1
KOCyr61 cells using a dye-
cycle-violet (DCV)-488 Alexa stained Panc-1 cells
using a flow cytometry technique [24]. DCV negative
cells are considered SP cells and stained cells are NSP
cells (Figure 7A). Consistent with previous works
[23,24], our studies demonst r a t et h a tt h e r ea r ea b o u t
10-15% SP cells in Panc-1 and this population can sig-
nificantly be reduced by several folds in the presence
of Verapamil (Figure 7Aand 7B), an inhibitor of ABC
transporter and known to inhibit side population in
various cancer cells [25]. Moreover, negligible percent
(less than 3%) of SP cells were detected in Panc-
1
KOCyr61 cells and these cells are Verapamil insensitive
(Figure 7Aand 7B). Finally, after isolation, both SP
and non-SP cells were grown for the determination of
Cyr61, epithelial and mesenchymal/stem cell markers
using Western blotting. SP cells are morphologically
spindle-shaped (Figure 8A), and over express Cyr61
along with CD44, Notch-1 and Oct-4. CD24, Keratin-
19 and b-catenin are down regulated in SP cells (Fig-
ure 8B). Blocking the expression of Cyr61 by shRNA
or a Cyr61 neutralizing antibody reduces the expres-
sion of stemness markers (i.e., CD44, Notch-1 and
Oct-4) (data not shown). Collectively, the data is con-
sistent with previous studies [23,24] indicating that SP
cells are enriched with stem cell properties. Cyr61
may play critical role in the formation of SP in Panc-1
cell lines.
Figure 3 Comparison of morphologies and expressions of EMT and stem cell markers in different pancreatic cancer cells. A. Photo-
micrographs of the morphology of different pancreatic cancer cells growing at low density on tissue culture plastic. B. Western blots analysis of
various epithelial, mesenchymal and stem cell markers. C. Diagrammatic illustration of aggressive/metastatic phenotypes of different pancreatic
cancer cells.
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Page 5 of 17Figure 4 Silencing of Cyr61 promotes mesenchymal to epithelial transition (MET) and blocks in vitro migration of Panc-1 cells.
A. Western blot illustrating shRNA mediated inhibition of Cyr61 expression in Panc-1 cells. B. The photomicrographs represent the
morphological changes (from mesenchymal to epithelial transition, MET) in mismatched and Cyr61 silenced Panc-1 cells. The morphology of
each cells are marked with yellow lines.C. The photomicrographs represent the difference in the in vitro migration of mismatched and Cyr61
silenced Panc-1 cells toward the serum for 24 hours. Results are averages ± SEM (n = 6). *p < 0.001 vs mismatched. D. Demonstration of the
inhibition of paracrine action of Cyr61 on migration toward the serum for 48 h by different doses of Cyr61 neutralizing antibody. Results are
averages ± SEM (n = 6). *p < 0.05 vs vehicle treated control; **p < 0.01 vs vehicle treated control and ***p < 0.001 vs vehicle treated control.
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Panc-1-SP cells can be blocked by silencing Cyr61
To observe the in vivo tumor growth potential of SP
cells, both SP and NSP cells (5 × 10
4) cells with Matri-
gel were injected into the rear flank of the each mouse
(5-9 mice/exp). At the sitew h e r et h eS Pc e l l sw e r e
injected, nine of 9 mice demonstrated tumor formation
10-15 days post injection with evidence of angiogenesis
(Figure 9). The xenograft tumors overexpressed Cyr61
and other markers. SP-tumors were developed in all
nine mice 20 days post injection. However, tumors were
not detected in the animals injected with NSP cells (Fig-
ure 9). Tumor formation was detected in two out of
5 mice 30 days post the injection of unsorted Panc-1
cells (data not shown). Our next goal was to find the
role of Cyr61 in tumor formation of SP cells in the
xenograft model. To do so, Cyr61 was silenced in SP
cells by stable transfection of a Cyr61-shRNA containing
retroviral. SP cells and Cyr61 silenced SP cells (SP
KO-
Cyr61) were injected into nude mice and tumor growth
Figure 5 Cyr61 silencing by RNAi (shRNA) (A) or blocking its paracrine activities by a Cyr61 neutralizing antibody (B) modulates the
expressions of different epithelial and mesenchymal/stemness markers in Panc-1 cells. Equal amount of cell lysates were analyzed by
Western blotting using specific antibodies. b-actin antibody was taken as a loading control.
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SP
KOCyr61 cells were unable to form tumor in the xeno-
graft even after 20 days post injection (Figure 9).C o l -
lectively, these studies suggest that Cyr61 may play a
critical role in stemness and tumor initiating capability
in a population of pancreatic cells.
Regulation of microRNA (miRNA) by Cyr61 in Panc-1 cells
To gain further insight into the factors critically regu-
lated by Cyr61 in pancreatic cancer cells, we established
quantitative miRNA expression profiles of candidate
markers in Cyr61 knockout Panc-1 cells. Prior to micro-
array analysis, the quality of each RNA sample was veri-
fied by determining the quality of RNA (Figure 10). The
miRNA expression analysis was carried out in three
independent culture samples and we performed pair
wise comparisons of each culture. Data was converted
into log2 ratios comparing levels of miRNA expression
in Cyr61
+ and Cyr61 knockout Panc-1 cells. We
observed a dramatic alteration in the miRNA expression
profiles in Cyr61 knockout Panc-1 cells and we identi-
fied miRNAs that are critically involved in EMT, migra-
tion and invasion, and stemness (Figures 10B and 10C).
In particular, we noticed an increased in the miR-200
family (miR-200a, miR-200b, miR-200c, miR-141 and
miR-429) in Panc-1
KOCyr61 cells (Figure 10B).T h i s
family of miRNAs is known to regulate EMT and tumor
aggressiveness [26]. Furthermore, the microRNAs, which
Figure 6 Induction of EMT and stemness by Cyr61 recombinant protein in Cyr61 negative BxPC-3 cells. A. The photomicrographs
represent the morphological changes in BxPC-3 cells growing in the presence and absence of recombinant Cyr61 protein (100 ng/ml) for 48 h.
The morphology of each cell is marked with black lines. B. Western blot analysis of various epithelial, mesenchymal and stem cell markers.
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Cry61+ and Panc-1
KOCyr61cells labeled with Vybrant DyeCycle Violet stain. (A). Side population
(SP) cells were detected in Panc-1
Cry61+ cells in absence of verapamil (upper left panel). Significant reduction in SP cells was observed in the
presence of 50μM verapamil (upper right panel). Lower left and right panels are showing the traces of SP cells in Panc-1
Cry61+ and Panc-
1
KOCyr61cells in the absence and presence of 50μM verapamil, respectively. Results are representative of three independent experiments. The SP
cells are outlined in the figure. (B). SP cells are shown in a bar diagram as a percentage of the total cell population.
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are upregulated, while those responsible for stem cell
generation [29] are down regulated in Cyr61-shRNA
transfected Panc-1 cells (Figure 10C). While future sys-
tematic Northern blots and in situ hybridization screens
in these cells and human tissue samples are required to
validate all miRNAs, we corroborated the differential
expression by qPCR in these cells and human pancreatic
cancer cells (data not shown).
Discussion
The present studies demonstrate that Cyr61 is an
important pancreatic cancer marker and that it plays a
novel pathobiological role in the development of PDAC.
First, we found that Cyr61 is consistently overexpressed
in early precursor lesions and its expression increased
with advancing disease. 81-85 percent of PDAC patients’
samples show Cyr61 positivity (Figure 1). Cyr61 expres-
sion was also detected in different PDAC cell lines.
However, the expression profiles were different among
the different cell lines. The aggressive cell lines, in
which expression profiles of mesenchymal/stem cell
molecular markers are predominant, exhibit more Cyr61
expression compared to less aggressive types (Figures 2
and 3). Second, we observed that Cyr61 plays a critical
regulatory role in EMT, stemness and migration of
Figure 8 Morphological and molecular characterization of the SP cells of Panc-1. A. Panc-1 cells were stained with dye-crystal-violet (DCV)-
488 Alexa and analyzed by flow cytometry. The representative images were depicted from three independent experiments. The
photomicrographs shown in the right panels represent the morphology of SP and NSP cells. B. Western blots analysis of Cyr61 and various
epithelial, mesenchymal and stem cell markers in SP and NSP cells.
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found that a Cyr61-positive side population (SP) of
Panc-1 cells is tumorigenic in a xenograft model and
prevention of Cyr61 expression by RNAi (shRNA) in SP
cells suppresses the tumor growth ability of these cells
drastically (Figure 9). Finally, depletion of Cyr61 expres-
sion by RNAi in Panc-1 cells prevented multiple
miRNA expressions that are known to regulate EMT,
stemness and migration (Figure 10). These results, col-
lectively, indicate that the activation of Cyr61 signaling
in pancreatic cancer cells is one of the early events and
is critically linked to the aggressive behavior of these
cells including EMT induction and reprogramming of
stemness in these cells.
Multiple studies from various laboratories have sug-
gested that PDAC mainly arises from pancreatic ducts
through sequential, atypical histological preneoplastic
changes (also known as pancreatic intraepithelial neo-
plasms; PanINs) leading to the development of well to
poorly differentiated cancers [30-32]. These sequential
transformation events require some oncogenic muta-
tions (i.e. K-ras and p53) [33] and/or aberrant expres-
sions of certain genes, reorganizing many cellular
features linked with cellular growth and survival. These
include EGFR (epidermal growth factor receptor)
[34,35], Notch-1 [36] and most importantly, the Hedge-
hog (Hh) signaling pathway [37,38]. We show that
Cyr61 is aberrantly overexpressed in histologically
defined precursor lesions (PanINs; PanIN-1A-PanIN-3)
and its mRNA and protein levels are markedly elevated
in varying grades of PDAC specimens compared to adja-
cent normal tissues where its expression was almost
undetected. Cyr61 expression was also differentially
expressed in different pancreatic cancer cell lines
depending on their morphological and pathobiological
behavior. Since several lines of evidence support the
role of Cyr61 in promotion as well as progression of
various cancers, the present studies highlight the impor-
tance of aberrant expression of Cyr61 in pancreatic
carcinogenesis.
Cyr61 showed increased expression in metastatic
lesions in a clinically relevant model of pancreatic ade-
nocarcinoma. This increase suggested that the interac-
tion between Cyr61 and avb3 may promote formation
of peritoneal metastases [17], yet its role in PDAC still
remains poorly understood. The acquisition of a meta-
static phenotype by cancer cells is a complex, multi-
step process. This process includes EMT followed by
stemness, migration and invasion [39,40]. Loss of Cad-
herin expression or function [41], aberrant regulation
of b-catenin [42], Notch-1 [43] and stemness [40] are
hallmarks of EMT. Our studies show that Cyr61,
which, when overexpressed in PDAC and its precursor
lesions (Figure 1), promotes EMT possibly through
down-regulating E-cadherin and its interacting part-
ners such as b-catenin (Figures 3, 4, 5, 6).I na nin
vitro setup, we have also demonstrated that stemness-
like state can be achieved in the presence of Cyr61
through the regulation of multiple stemness traits
including ABCG2, Notch-1, Oct-4 and CD-44 in pan-
creatic cancer cells. Moreover, we also found that
Cyr61 is a positive regulator of the pancreatic cancer
cell migration, one of the hallmarks of cancer that
leads cancer cells to invade for metastatic growth to
the distant organs. Collectively, from these experi-
ments, we assumed that the activation of Cyr61/CCN1
may play a critical role in the reprogramming and
maintenance of cancer stemness/tumor initiating cells
through EMT process in parental counterparts, and
subsequently enhance the migration of these cells. We
are not aware though of any data that support this
idea (i.e., EMT instigates stemness) other than the
reports of Mani et.al.[ 4 0 ] .
The above perception of Cyr61/CCN1 is further
strengthened with our side-population (SP) studies (Fig-
ures 7and 8). These studies showed that a side popula-
tion (SP) of pancreatic cancer cells, which has
mesenchymal/stemness features, produced a sc tumor
with overexpressed Cyr61in nude mice within a brief
period (Figure 9).R N A i-based nullification of Cyr61 in
SP cells reverses the cellular and molecular features of
SP cells, and they behave like the non-side population
(NSP). In addition, Cyr61 knockout cells are unable to
develop tumor xenograft tumors in nude mice. Taken
together, these studies suggest that Cyr61 seems to par-
ticipate in SP generation and SP-tumorigenicity as well.
Figure 9 In vivo tumorigenicity.S P ,N S Pa n dS P
KOCyr61 cells were
grown in DMEM with 10% FCS. ~5 × 10
4 cells were injected s.c.
into the right real flank of nude mice and tumor growth was
monitored. The number of mice with tumors in each experimental
set-up has been presented in the table.
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this distinctive process are uncertain. It will be, there-
fore, interesting to define how Cyr61 deficiency regu-
lates reprogramming by promoting mesenchymal to
epithelial transition in pancreatic cancer cells and what
specific factor(s) are crucial for leading to a side popula-
tion state under the influence of Cyr61.
Multiple studies have shown an analogous connection
between cancer progressions related events and the
expression profiles of miRNAs, an abundant class of non-
protein-coding RNAs that function as negative regulators
of diverse functional genes [44]. Recent studies have
shown that miRNA mutations, mis-expression and mal-
function of miRNA machinery correlate with various
human cancers’ development and progression [44]. In
particular, miRNAs of miR-200 family appear to play a
critical role in the regulation of EMT and tumor aggres-
siveness [26] and eventually may play a role in generating
Figure 10 Expression profiling of microRNA in mismatched and Cyr61-shRNA transfected Panc-1 cells. C. The left panel shows the 28S
and 18S bands of total RNA extracted from mismatched-shRNA and Cyr61-shRNA transfected Panc-1 cells. The middle and right panels depict
the electropherograms of total RNA validating its integrity. D. After data set normalization, the Log2 of the relative quantification for specific
miRNAs associated with inhibition of EMT and migration/invasion was plotted as a bar graph. The right panel shows a heat map comparing the
average fold-changes in microRNAs with significantly higher (red) or lower (green) expression in Cyr61-shRNA transfected Panc-1 cells in
comparison to mismatched-shRNA transfected Panc-1 cells as determined by miRNA Array analysis. Then the signal was globally normalized and
Average Linkage Clustering was performed using a Euclidean Correlation. Clustering was visualized using the program provided by Applied
Biosystems, Foster City, CA. E. Profiling of microRNAs associated with stem cell traits.
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from different miRNA profiling experiments it is evident
that miRNAs can act as stemness regulators [45]. We
have shown here that Cyr61 regulates some of the above
mentioned miRNAs that are associated with EMT, stem-
ness and migration/invasion activities (Figure 10). There-
fore, these studies raise the possibility that Cyr61-
induced EMT, stemness and migration activity may be
driven by the regulation of miRNAs. However, further
studies will certainly be required to establish the hypoth-
esis and in vivo significance of the cell culture findings,
which are in progress.
Conclusions
In conclusion, these studies, as depicted in Figure 11,
identify Cyr61/CCN1 as a critical regulator of pancreatic
carcinogenesis by making an essential contribution in
the development of aggressive phenotypes (i.e., EMT fol-
lowed by stemness) of this disease. These contributions
may potentiate through the regulation of miRNAs.
Given that Cyr61 activity is crucial for pancreatic cancer
cell growth and progression, targeting the Cyr61 path-
way may be an attractive therapeutic avenue in PDAC.
Materials and methods
Reagents and antibodies
Human polyclonal anti-rabbit Cyr61 antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
Monoclonal anti-mouse GAPDH antibody was purchased
from Applied Biosystems (Foster City, CA). Mouse
monoclonal Vimentin antibody was obtained from Lab
Vision (Fremont, CA), mouse monoclonal anti-b-catenin
and rabbit polyclonal Keratin-19 were purchased from
BD Transduction Laboratory (San Jose, CA), rabbit poly-
clonal anti-human Oct-4 and CD44 were purchased from
Cell Signaling (Boston, MA). Rabbit polyclonal anti-
human Notch-1, mouse monoclonal anti-human CD24,
polyclonal goat anti-rabbit IgG-HRP and monoclonal
goat anti-mouse IgG-HRP were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Cyr61 recombi-
nant protein was purchased from Thermo Fisher Scienti-
fic (Waltham, MA). pSilencer™ 5.1-U6 retroviral vector
and siPORT™ XP-1 transfection agent were obtained
from Applied Biosystems (Foster City, CA). Matrigel was
purchased from BD Biosciences (Bedford, MA). All other
chemicals were obtained either from Sigma (St. Louis,
MO) or Fisher Scientific (Houston, TX).
Tissue samples
Archived, 4% formalin-fixed, paraffin-embedded primary
pancreatic adenocarcinoma samples and chronic pan-
creatitis tissue samples were obtained from the Depart-
ment of Surgical Pathology of VA Medical Center. The
pancreatic tissue array containing adjacent normal (NP),
chronic pancreatitis (CP) and different grades of ductal
adenocarcinoma (Gr-I, Gr-II and Gr-III) were evaluated
in this study. The tissue arrays were purchased from
Cybrdi Inc (Frederick, Maryland).
Cell Culture
All Pancreatic cancer cell lines (i.e., BxPC-3, AsPC-1,
Capan-1, and Panc-1) were purchased from American
Type Culture Collection (ATCC, Manassas, VA). The
cell lines were cultured in Dulbecco’s modified Eagle’s
medium (Sigma, St Louis, MO) supplemented with
1 0 %f e t a lb o v i n es e r u m( H y c l o n e ,L o g a n ,U T ) ,2m M
glutamine, 100 units/ml penicillin and 100units/ml
streptomycin (Sigma) at 37°C incubator in the presence
of 5% CO2. Ampho-pak 293 packaging cell line was
purchased from Clontech (California, USA), and was
maintained in high glucose DMEM containing 10%
FBS. Cells were used for the experiment between four
and six passages.
Immunohistochemistry
The Immunohistochemistry was performed on 4% for-
malin fixed-paraffin-embedded tissue sections according
to our previous method [46,47]. Briefly, tissue sections
were deparaffinized in Xylene, rehydrated in different
grades of alcohol, washed with PBS and blocked with
tissue blocker (Zymed Laboratories, CA) for 10 minutes
and immunostained by polyclonal human anti-rabbit
Cyr61 antibody (1:300) overnight. The clinical stages
obtained from database were reviewed and reconfirmed
by a pathologist using adjacent hematoxylin and eosin
stained slides. The sections were imaged with a Leica
photomicroscope. All samples were used according to
VA Medical Center and University guidelines after
receiving Institutional Review Board approval.
RNA Extraction, cDNA Synthesis, and Probe Preparation
Total RNA extraction was essentially the same as that
previously described [46,47]. cDNA synthesis and probe
Figure 11 Diagrammatic illustrations of Cyr61/CCN1 signaling
involved in EMT, stemness and development and progression
of pancreatic cancer. The studies speculate that multiple miRNAs,
which are actively participate in different phases of carcinogenesis,
are participated in Cyr61/CCN1-based carcinogenesis.
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described by Banerjee et al [46].
In Situ Hybridization
In situ hybridization for Cyr61 mRNA expression was
performed on formalin-fixed, paraffin embedded tissue
sections according to the method that is described ear-
lier by us [48]. Briefly, the paraffin sections were
dewaxed in xylene, rehydrated through different grades
of alcohol and digested with proteinase K followed by
post-fixation in 10% formaldehyde solution at room
temperature. The sections were thoroughly washed
with RNAse-free water and incubated with Digoxi-
genin (DIG)-labeled PCR generated Cyr61 specific non-
radioactive probe (250 ng/ml) overnight at 37°C in a
humidified hybridization chamber. The hybridized probe
was detected using alkaline phosphatase-conjugated
anti-DIG antibody (InnoGenex) and visualized with
chromogen combination 5-bromo-4chloro-3-indolyl
phosphate NBT.
Northern blot Analysis
For Northern blotting, an established method previously
reported by us was used [49]. Briefly, Total RNA (10 μg)
of each sample was separated by formaldehyde/agarose
gel electrophoresis and transferred to a nylon mem-
brane. The membranes were hybridized with nonra-
dioactive digoxigeninlabeled, PCR-generated probes.
Glyceraldehyde- 3-phosphate dehydrogenase (GAPDH)
was used as a loading control. Relative expressions of
mRNA were calculated by densitometric analyses using
One-dimensional Image Analysis Software version 3.6
(Eastman Kodak Co., Rochester, NY).
Quantitative real-time PCR
Briefly, total RNA was extracted from different pancrea-
tic cancer cell lines using TRIZOL (Invitrogen, Carlsbad,
CA). cDNA was prepared from total RNA by using Taq-
man Reverse Transcription kit. Real-time PCR was per-
formed from cDNA products using Taqman universal
PCR and Taqman assay kit by Applied Biosystem Step
One real-time PCR system. CT values for Cyr61 were
normalized to human GAPDH by subtracting the aver-
age CT value for each sample. Relative quantification
(RQ) values for Cyr61 in each sample were determined
using the 2
-ΔΔCT method [47]. Each PCR reaction was
performed in triplicate.
Western Blot Analysis
Cell lysates from different pancreatic cell lines were pre-
pared for Immuno-Western blotting according to our
previous method [46]. Briefly, cells were washed with
phosphate-buffer saline (PBS) and lysed in RIPA buffer
( 5 0m Mt r i s - C l ,p H8 . 0 ,1 5 0m MN a C l ,1 %N o n i d e t
P-40, 0.1% sodium dodecyl sulfate) containing the pro-
tease inhibitors, 0.5 mM phenylmethylsulfonyl fluoride,
1μM leupeptin, 1μM aprotinin. The lysates were centri-
fuged at 18000 rpm for 60 min at 4°C. Equal amounts
of protein (50 μg), as determined by Coomassie blue
reagent assay (Bio-Rad, Richmond, CA), were subjected
to 10% SDS-PAGE, and the gel-fractionated proteins
were transferred to nitrocellulose membranes (Bio-Rad)
and reacted with appropriate antibodies. Signals were
detected with Super Signal ULTRA chemiluminescent
substrate (Pierce, Rockford, IL) by using one dimen-
sional Image analysis, version 3.6 (Eastman Kodak Co.,
Rochester, NY).
Retroviral production and transduction of cells
Human Cyr61-shRNA primers were designed using
vector NTI software from Invitrogen. The shRNAs
sequences of human Cyr61 are: shRNA-1, forward:
5’-GAT CCG GGA AAG TTT CCA GCC CAA TTC
AAG AGA AGT TGG GCT GGA AAC TTT CCC
TTT TTT GGA AA -3’; reverse: 5’-A G CT T TT C C
AAA AAA GGG AAA GTT TCC AGC CCA ACT TCT
CTT GAA TTG GGC TGG AAA CTT TCC C -3’;
shRNA-2, forward: 5’- GAT CCG CCC AAC TGT AAA
CAT CAG TTC AAG AGA CAC TGA TGT TTA CAG
TTG GGC TTT TTT GGA AA -3’; reverse: 5’-A G C
TTT TCC AAA AAA GCC CAA CTG TAA ACA TCA
GTG TCT CTT GAA CTG ATG TTT ACA GTT GGG
C- 3 ’. Recombinant clones of Cyr61shRNA are produced
using pSilencer™5.1-U6 Retro-viral Vector from Ambion
(Austin, TX) as per the protocol described in the
instruction manual. Recombinant clones were confirmed
by sequencing using sequencing primers. Scrambled
control provided in the kit was used as a control. Briefly,
Cyr61shRNA is transfected in Amphopak ™293 packa-
ging cell line using siPORT™ XP-1 transfection agent.
Supernatant containing viral particles was collected after
72 h. ~60% Panc-1 cells were infected with Cyr61-
shRNA containing viral supernatant or scrambled con-
trol with different dilutions (from 1:10
1 to 1:10
5)a n d
incubated for 72 hrs. Stable cell lines were prepared
after prolonged puromycin treatment. Stable cells were
then cultured in regular DMEM media with 10% FBS
and harvested for western or northern blot analysis to
check the transfection efficiency.
MicroRNA (miR) Array Analyses
For miRNA array experiments, total RNA was isolated
from mismatched-shRNA and Cyr61-shRNA transfected
Panc-1 cell lines by Trizol method as described in the
prior section. The integrity of total RNA was assessed
by running RNA sample on a denaturing agarose gel
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18S are considered as a good indication of intact RNA.
cDNA was synthesized using Megaplex RT PCR kit
(Applied Biosystems, Foster City, CA) for Array A,
which contains 384 stem-looped reverse transcription
primers specifically binds to miRNAs. Briefly, 500 ng of
total RNA and 4.5μl of RT reaction mix in a total
volume of 7.5μl were processed for cDNA preparation
at the following cycle conditions: 16°C for 2 min, 42°C
for 1 min and 50°C for 1 min for total of 40 cycles fol-
lowed by 85°C for 5 min and bringing the contents to
4°C. The human miRNA array system (Array A)
(Applied Biosystems, Foster City, CA) was used for the
detection and quantification of miRNA in mismatched-
shRNA and Cyr61-shRNA transfected Panc1 cells. This
miRNA-array kit consists of four plates of plate A and
four plates of plate B which contain around 384 miR-
NAs including four internal controls. For this we used
6μl of cDNA synthesized by using Megaplex RT and
450 μl of TaqMan universal PCR master mix in a total
of 900 μl of reaction volume and 100 μlo ft h er e a c t i o n
mixture was loaded into each port provided in the card
(which has 8 ports for each card). The cards were run
in Applied Biosystems Real-time PCR system (7900 HT)
by selecting relative quantification (ΔΔC t )a tf o l l o w i n g
conditions: 95°C for 10 min, 95°C for 1 min and 60°C
for 1 min for total of 40 cycles. All the samples were
run in duplicates. Finally, all the raw data from each
card was retrieved from the 7900HT machine and was
run on Data Assist Software ver.1.2 (Applied Biosystems,
Foster City, CA). The mean values for RQ (which is fold
values of Cy61-shRNA transfected compared to mis-
matched-shRNA transfected panc1 cell lines) were used
to plot the bar diagrams and heat map clusters.
In vitro Boyden chamber migration assay
The chemotaxis assay was conducted using a modified
Boyden chamber technique as described previously [46].
Briefly, Panc-1 cells (20,000 cells/well), which were
either infected with viral particles containing shRNA
(Cyr61/scrambled) or treated with Cyr61 neutralizing
antibody for 48 h, were added to the upper chambers of
the Boyden chamber (8 micron) containing DMEM with
1% FBS. Lower chamber was loaded with DMEM with
10% FBS. Cells were allowed to migrate for 24 hrs. The
migratory cells that were attached on the undersurface
of Boyden chamber were stained with crystal violet solu-
tion for 10 min. Inserts were washed with tap water and
then air dried for 30 minutes. Crystal violet stained cells
were solubilized with 10% acetic acid and optical density
is quantitated in Microplate reader at 600 nm. Three
wells were examined for each condition and the experi-
ments were repeated three times.
Isolation of side population (SP) by Flow cytometry
The side population/stem cells from Panc-1 cell line were
isolated according to the previous methods with brief mod-
ifications [24]. Briefly, ~80 percent confluent cells were
incubated with dissociation solution (Sigma Chemical Co.
St. Louis) for 15 min at 37°C, and dissociated cells
were counted and transferred to a 5 ml tube. Washed
twice with pre-warmed DMEM containing 10% FBS.
Finally, cells were resuspended in same media at concen-
t r a t i o no f1×1 0
6cells/100μl. Vybrant-Violet solution
(10μM) and Verapamil (50 μM) solution were added into
the sample and incubated at 37°C for 90 min. After incu-
bation, cells were centrifuged, and resuspended in ice-cold
1 × PBS, pH 7.4. 2μg/ml propidium iodide was added
immediately before flow cytometry analysis to exclude
dead cells. SP cells were identified, sorted, and analyzed on
a BD FACS Aria SORP flow cytometer (BD Biosciences)
using ~405 nm excitation and 440 nm emission. Sorted
cells (i.e., SP and Non-SP) were washed in serum-free
medium and then cultured in DMEM with 10% FCS for
several days in 5% CO2 at 37°C. The cell lysate was
extracted from semi-confluent cells for the analysis of dif-
ferent epithelial, mesenchymal and stem cell markers by
Western blot analysis using specific antibodies.
Sorted cell implantation in athymic nude mice
Male athymic nude mice (nu/nu genotype), 6 to
8 weeks old, were obtained from Charles Rivers
(Wilmington, MA) and acclimated in our facility for
1 week. The animal studies were conducted according
to the approved Guidelines of the Animals Care and
Use Committee of Kansas City VA Medical Center.
Sorted cells (SP and NSP) were grown in DMEM with
10% FCS using the same procedure as described herein.
Cells (5 × 10
4)w e r ei n j e c t e ds.c.i n t ot h er i g h tr e a r
flank of each mouse (5-9 mice per group) and tumor
growth was monitored after 2
nd days of injection and
continued up to 21 days.
Statistical Analysis
The results of each experiment were the representative of
at least three sets of experiments performed in triplicate.
All data were expressed as the mean ± SEM. Statistically
significant differences between groups were determined
by using the non paired Student’st w o - t a i l e dt-test. A
value of P < 0.05 was considered statistically significant.
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